Table 7.
Best ranked terms extracted from Paper1 using F-TFIDF-C_M
| F-TFIDF-C_M | |||||
|---|---|---|---|---|---|
| Title Corpus | Abstract Corpus | Content Corpus | |||
| terms | rank | terms | rank | terms | rank |
| Respiratory syncytial virus | 1.9880 | Public health | 1.9986 | Additional file | 1.9976 |
| Middle east respiratory syndrome coronavirus | 1.9846 | Infectious diseases | 1.9979 | Infectious disease | 1.997 |
| Systematic review | 1.9842 | Immune responses | 1.9976 | nk cells | 1.997 |
| Open access | 1.9819 | Influenza virus | 1.9976 | Health care | 1.996 |
| Zika virus | 1.9819 | t cells | 1.9975 | Endothelial cells | 1.9957 |
| Gene expression | 1.9795 | Virus infection | 1.9974 | Frequency domain | 1.9957 |
| Virology journal | 1.9788 | Respiratory tract | 1.9973 | Ebola virus | 1.9948 |
| Human coronavirus | 1.976 | Viral infections | 1.9969 | Influenza infection | 1.9943 |
| Case report | 1.9756 | RNA viruses | 1.9967 | Real-time rt-pcr | 1.9933 |
| Syncytial virus | 1.9752 | Acute respiratory syndrome | 1.9961 | Incubation period | 1.99325 |
| t cell | 1.9746 | 95percent ci | 1.996 | Health emergency | 1.9932 |
| Infectious bronchitis | 1.9726 | Ebola virus | 1.9945 | Index patient | 1.9932 |
| Sars coronavirus | 1.9723 | Influenza viruses | 1.9943 | Membrane rafts | 1.9931 |
| BMC public health | 1.9701 | Avian influenza | 1.9939 | pcr products | 1.9929 |
| t cells | 1.9689 | Respiratory tract infections | 1.9938 | 2c atpase | 1.9926 |
| Acute respiratory infection | 1.9672 | Health care | 1.9925 | b cell | 1.9924 |
| Mini review | 1.9636 | Hepatitis c | 1.9922 | Close contact | 1.9924 |
| Respiratory viral infections | 1.9636 | Type I | 1.9918 | Final dataset | 1.9922 |
| BMC public | 1.9625 | Cell line | 1.9914 | 3d8 scfv | 1.9921 |
| Ebola virus disease | 1.9592 | Spike protein | 1.9909 | Pol ii | 1.992 |
| Supplementary information | 1.9574 | Codon usage | 1.9908 | 3c pro | 1.992 |
| Community-acquired pneumonia | 1.9543 | Pandemic influenza | 1.9907 | Influenza pandemic | 1.9919 |
| Global health | 1.9543 | Endoplasmic reticulum | 1.9904 | Phylogenetic tree | 1.9918 |
| Peer review | 1.9543 | Saudi Arabia | 1.9904 | Protein vi | 1.9917 |
| Japanese encephalitis virus | 1.9512 | Innate immunity | 1.9903 | ag nps | 1.9916 |
| Innate immunity | 1.9488 | Porcine epidemic | 1.9903 | Influenza b | 1.99125 |
| Multiple sclerosis | 1.9488 | Global health | 1.9902 | ifn | 1.991 |
| Human rhinovirus | 1.9466 | Vaccine development | 1.9901 | ill patients | 1.9908 |
| Supplementary material | 1.9442 | Cell death | 1.9898 | Poly tail | 1.9908 |
| Cell entry | 1.9417 | Infectious disease | 1.9896 | Host range | 1.9906 |
| Coronavirus spike | 1.9417 | Peripheral blood | 1.9895 | Cyclin d3 | 1.9903 |
| Human adenovirus | 1.9417 | Hong Kong | 1.9894 | Sequence accession | 1.9903 |
| East respiratory syndrome coronavirus | 1.9414 | Immune cells | 1.9888 | Antiviral drugs | 1.9897 |
| Mers coronavirus | 1.9388 | Cell cycle | 1.9886 | Subunit vaccines | 1.9897 |
| West Africa | 1.9388 | Clinical trials | 1.9885 | Protein sequences | 1.9895 |
| Molecular epidemiology | 1.9323 | Infection control | 1.9884 | Oil spill | 1.9895 |
| National natural science | 1.931 | Mass spectrometry | 1.9883 | Swine flu | 1.9894 |
| Natural science foundation | 1.931 | Genome sequence | 1.9881 | Membrane proteins | 1.9893 |
| Rift valley fever | 1.931 | Clinical samples | 1.9877 | Contact tracing | 1.9891 |
| National natural science foundation | 1.9307 | Acute respiratory infections | 1.9874 | sars 3a | 1.9889 |
| Influenza infection | 1.9284 | Severe disease | 1.9868 | Critical care | 1.9888 |
| Protein response | 1.9284 | Hepatitis b | 1.9864 | hk-2 cells | 1.9888 |
| Science foundation | 1.9284 | Host response | 1.9864 | ap2 group | 1.9887 |
| Supplementary materials | 1.9284 | Type II | 1.9864 | prp sc | 1.9887 |
| Natural science | 1.9241 | Nucleic acids | 1.9862 | t-cell responses | 1.9887 |
| Respiratory syndrome coronavirus infection | 1.9241 | Surveillance systems | 1.9859 | DNA vaccines | 1.9886 |
| Influenza virus | 1.9212 | Influenza virus infection | 1.9852 | Reverse genetics | 1.9886 |
| Obstructive pulmonary disease | 1.92 | Antiviral drugs | 1.9851 | Health system | 1.9884 |
| Emerging microbes | 1.9193 | DNA vaccine | 1.9847 | 1.9884 | |
| Original research | 1.9193 | Influenza infection | 1.9845 | hcv infection | 1.9883 |
| Retrospective study | 1.9193 | Reference genes | 1.9842 | Lung cancer | 1.9879 |
| Phylogenetic analysis | 1.9153 | Cell types | 1.984 | Nucleocapsid protein | 1.9879 |
| Respiratory syndrome coronavirus | 1.9151 | b cell | 1.9835 | 3c protease | 1.9878 |
| Clinical characteristics | 1.9138 | Vaccine candidates | 1.9835 | tgev infection | 1.9878 |
| Mass spectrometry | 1.9138 | Host species | 1.9833 | cs dna | 1.9878 |
| National natural | 1.9138 | Respiratory viral infections | 1.9832 | Risk perception | 1.9875 |
| Rift valley | 1.9138 | Endothelial cells | 1.9829 | s1 protein | 1.9875 |
| Science china | 1.9138 | Sequence data | 1.9829 | Ring vaccination | 1.9875 |
| Valley fever | 1.9138 | DNA viruses | 1.9826 | Syrian hamster | 1.9873 |
| Respiratory virus infections | 1.913 | Host innate | 1.9826 | Wild mice | 1.9873 |
| Syndrome coronavirus | 1.9096 | Parainfluenza virus | 1.9824 | Yellow fever | 1.9873 |
| Classical swine fever virus | 1.9087 | Tract infections | 1.9822 | Climate change | 1.9873 |
| b cells | 1.9074 | South Korea | 1.9821 | Public health services | 1.9873 |
| Host response | 1.9074 | Acute respiratory infection | 1.9817 | Index patients | 1.9872 |
| Science foundation of china | 1.9074 | Reproduction number | 1.9816 | Small rna | 1.9872 |
| Viral proteins | 1.9074 | Surveillance system | 1.9816 | IC activity | 1.9871 |
| Virus disease | 1.9065 | Causative agent | 1.9813 | Ebola virus disease | 1.9868 |
| Clinical infectious diseases | 1.9048 | Multiple sclerosis | 1.9811 | RNA chaperone | 1.9867 |
| World health organization | 1.9048 | rsv infection | 1.9809 | Caco-2 cells | 1.9867 |
| Antiviral agents | 1.9001 | Cellular proteins | 1.9808 | m2 channel | 1.9865 |
| Cell culture | 1.9001 | West nile virus | 1.9806 | Overlapping genes | 1.9865 |
| Pulmonary disease | 1.9001 | Respiratory diseases | 1.9805 | Nasal mucosa | 1.9865 |
| Study protocol | 1.9001 | tgev infection | 1.9805 | Hepatitis e | 1.9865 |
| Dengue virus | 1.8946 | e protein | 1.9802 | Genetic drift | 1.9865 |
| Public health | 1.893 | Gene expression | 1.9801 | a7 gfp | 1.9865 |
| RNA replication | 1.8915 | Structural proteins | 1.9799 | Tumor cells | 1.9864 |
| Japanese encephalitis | 1.8902 | Acute respiratory tract | 1.9792 | Tanguticum nanoparticles | 1.9864 |
| Syndrome coronavirus infection | 1.8864 | Hand hygiene | 1.9792 | cfu ml | 1.9864 |
| Human respiratory syncytial virus | 1.8841 | Disease transmission | 1.9788 | Ward closure | 1.9861 |
| Synonymous codon usage | 1.8824 | Human rhinovirus | 1.9785 | Case definitions | 1.9861 |
| Clinical infectious | 1.8813 | Bacterial infections | 1.9781 | Richards model | 1.9861 |
| Health organization | 1.8813 | Cancer cells | 1.9781 | Epimedium koreanum | 1.9861 |
| Severe pneumonia | 1.8813 | DNA vaccines | 1.9777 | ms2 plp | 1.986 |
| Dengue virus infection | 1.8772 | Type III | 1.9777 | Gene therapy | 1.9859 |
| Clinical samples | 1.8768 | Viral pathogenesis | 1.9773 | Integrin b3 | 1.9859 |
| Classical swine fever | 1.8744 | Zoonotic diseases | 1.9773 | Cardiovascular diseases | 1.9859 |
| Human antibody | 1.869 | Early detection | 1.9765 | Fourth site | 1.9859 |
| Lassa virus | 1.869 | Lung cancer | 1.9756 | Serial interval | 1.9858 |
| Pilot study | 1.869 | Nile virus | 1.9756 | trm cells | 1.9858 |
| Avian influenza viruses | 1.8667 | Human disease | 1.9751 | Electronic supplementary material | 1.9857 |
| Human respiratory syncytial | 1.8667 | rnase l | 1.9751 | Emergency nurses | 1.9856 |
| International health regulations | 1.8667 | Health systems | 1.9746 | Pet substrate | 1.9856 |
| Hepatitis c virus infection | 1.8661 | Incubation period | 1.9746 | fcov type | 1.9856 |
| Infectious bronchitis virus strain | 1.8661 | Rabies virus | 1.9746 | s1 text | 1.9856 |
| Vaccine development | 1.8601 | Adaptive immunity | 1.9741 | Global health research | 1.9854 |
| Protects hepatocytes from type I | 1.8564 | Multiplex pcr | 1.9741 | ace2 activity | 1.9853 |
| Type I interferon signaling disrupts | 1.8564 | nk cells | 1.9741 | 6 ko | 1.9853 |
| Adaptive immunity | 1.8538 | Feline coronavirus | 1.9735 | Global health | 1.9852 |
| Adenovirus type | 1.8538 | Human populations | 1.9735 | Ham tsp | 1.9851 |
| Nonhuman primates | 1.8538 | Common cold | 1.9723 | Blood culture | 1.9849 |